Skip to main content
. Author manuscript; available in PMC: 2016 Mar 15.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):721–729. doi: 10.1016/j.ijrobp.2014.12.023

Figure 1.

Figure 1

Cumulative incidence estimates of local-regional relapse (Panel A) and distant metastasis (Panel B) and Kaplan-Meier estimates of progression-free survival (Panel C) and overall survival (Panel D) for patients with baseline primary MTV ≤ median or > median. Two-year local-regional relapse rates were 5.7% (95% CI: 0, 13.5) for patients with MTV ≤ median and 30.3% (95% CI: 14.3, 46.3) for patients with MTV > median. Two-year distant metastases rates were 2.9% (95% CI: 0, 8.5) for patients with MTV ≤ median and 12.1% (95% CI: 0.8, 23.4) for patients with MTV > median. Two-year progression-free survival rates were 88.6% (95% CI: 78.0, 99.1) for patients with MTV ≤ median and 63.6% (95% CI: 47.2, 80.0) for patients with MTV > median. Two-year overall survival rates were 94.3% (95% CI: 86.6, 100) for patients with MTV ≤ median and 84.9% (95% CI: 72.6, 97.1) for patients with MTV > median.